
$32.4m revenue and $4.3m EBITDA recorded in Q1 FY27 as Citi approves refinancing $CLG stockwirex.com/asx-stock-new…

StockWire X is a digital investor publication dedicated exclusively to ASX-listed companies outside the mining sector.

$32.4m revenue and $4.3m EBITDA recorded in Q1 FY27 as Citi approves refinancing $CLG stockwirex.com/asx-stock-new…

Gimbal up, buyout news in hand, and both sides of the story in plain English. Genius or chaos? Now you can see the bull and bear case together. Join the StockWire X founding waitlist. First 1,000 lock in A$247 a year, for life. Link in bio. #ASX #Investing #BullAndBear #ShareMarket #StockWireX

Revenue up 27% to $36.7m as @ChrysosCorp reported July to October trading $C79 stockwirex.com/asx-stock-new…

Revenue up 27% to $36.7m as @ChrysosCorp outlined a strong FY27 start with 4.91m samples $C79 stockwirex.com/asx-stock-new…

3 Australian sites ready as Amplia's ACCENT-Mini pancreatic trial gains ethics approval $ATX stockwirex.com/asx-stock-new…

$64.8m record first-half Operating Profit as @AustAgCo outlined HY27 results $AAC stockwirex.com/asx-stock-new…

Macro commentary rarely names a single stock. Our topic hubs do: rates, AI, medtech and more, anchored to named ASX companies. Join the waitlist: the first 1,000 lock in A$247 a year, for life. waitlist.stockwirex.com/?utm…

$49.0m record 1H27 Underlying EBITDA, up 18%, as Oceania Healthcare turns cash positive $OCA stockwirex.com/asx-stock-new…

$331M gross revenue, +18% as @cettireofficial lifts YTD-FY27 adj. EBITDA to $6.9M $CTT stockwirex.com/asx-stock-new…

Three Monash IVF labs now use Felix™ as @memphasys national rollout proceeds $MEM stockwirex.com/asx-stock-new…

Stop bridging the theme and the stock yourself. StockWire X topic hubs pair AI, inflation and medtech research with the ASX names exposed. Join the waitlist: the first 1,000 lock in A$247 a year, for life. waitlist.stockwirex.com/?utm…

A$210-215m FY27 EBITA guidance after record Q1 as Tasmea lifts outlook again $TEA stockwirex.com/asx-stock-new…

Microba lacks funds to complete deal; @GeneticSig ends merger, refocusing on $GSS diagnostics Visit: stockwirex.com/asx-stock-new…

Microba lacks capital to complete merger as @GeneticSig halts deal $GSS stockwirex.com/asx-stock-new…

Genetic Signatures ends Microba merger after Microba lacks funds to complete, @GeneticSig $GSS Read more: stockwirex.com/asx-stock-new…

$19M to $20M FY27 revenue guidance as @IDTAus forecasts return to positive EBITDA $IDT stockwirex.com/asx-stock-new…